Upload
dothu
View
217
Download
5
Embed Size (px)
Citation preview
PharmacoEconomics & Outcomes News 339 - 17 Nov 2001
■ The HMG CoA reductase inhibitor [statin]atorvastatin [‘Lipitor’; Pfizer], has garnered a Q3 salesincrease of nearly 40% following the withdrawal ofcerivastatin [‘Baycol’; Bayer], reports the Pink Sheet.According to Pfizer CEO Henry McKinnell it appearsthat atorvastatin picked up about 40% of the availablecerivastatin scripts, while simvastatin [‘Zocor’; Merck& Co.] and pravastatin [‘Pravachol’; Bristol-MyersSquibb] have each gained < 30% of the total. Q3 salesfor these 3 agents combined increased nearly 40% to$US4 billion – clear evidence that the statin market isnot suffering in the wake of cerivastatin’s withdrawal.Statin market growth unaffected by Baycol, Pfizer says: Lipitor up 40%. FDCReports - Pink Sheet - Prescription Pharmaceuticals and Biotechnology 63:21-22, 29 Oct 2001 800876425
1
PharmacoEconomics & Outcomes News 17 Nov 2001 No. 3391173-5503/10/0339-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved